Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiaKine Therapeutics Inc.

Division of Islet Sciences Inc.
www.diakine.com

Latest From DiaKine Therapeutics Inc.

Beta/Islet Cell Regeneration Leads Diabetes Deal-Making This Decade

A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, April 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Islet Sciences buys Diakine in diabetes merger

Islet Sciences, which is developing products for insulin-dependent diabetes around its islet cell transplantation technology, is to acquire DiaKine Therapeutics in an all-share deal. DiaKine is developing novel immune modulators to treat diabetes and related conditions.

Metabolic Disorders Orthopedics

Start-Up Previews (12/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The Double-edged Sword of Diabetes Drug Development, features profiles of Alba Therapeutics, Alinea, DiaKine and Diabetica. Plus these Start-Ups Across Health Care: Actimis, Luminous Medical, NABsys and Pathfinder Therapeutics.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Islet Sciences Inc.
  • Senior Management
  • Keith D Ignotz, CEO
    Jerry L Nadler, MD, CSO
  • Contact Info
  • DiaKine Therapeutics Inc.
    Phone: (434) 975-2001
    1414 Sachem Pl., Ste. 3
    Charlottesville, VA 22901
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register